Showing 411-420 of 834 results for "".
Retina in Review
https://modernod.com/topics/retina/retina-in-review/38713/An overview of the latest developments and findings related to the treatment and management of diseases of the posterior segment.Ocular Surface Dryness in Women
https://modernod.com/topics/ocular-surface/ocular-surface-dryness-in-women/38110/An examination of the changing ocular surface through the stages of life.Systemic Comorbidities and Ocular Surface Dryness
https://modernod.com/topics/ocular-surface/systemic-comorbidities-and-ocular-surface-dryness/38260/Taking a thorough systemic case history can prompt eye care providers to screen patients for ocular surface issues.Inside the Innovator’s Mind
https://modernod.com/mod-issues/2022-mar/inside-the-innovators-mind/38391/What does it take to be a game-changer in optometry? Hear from four innovators who’ve run the gamut.- Jay S. Duker, MD, Named President and CEO of Eyepoint Pharmaceuticalshttps://modernod.com/news/jay-s-duker-md-named-ceo-of-eyepoint-pharmaceuticals/2481715/EyePoint Pharmaceuticals announced the appointment of Jay S. Duker, MD, as President and Chief Executive Officer. Dr. Duker has transitioned from his most recent role as Chief Operating Officer (COO) and President. Dr. Duker has also been appointed to the Board of Di
- EyeCheq adds Jai G. Parekh, MD, to its Executive Teamhttps://modernod.com/news/eyecheq-adds-jai-g-parekh-md-mba-to-its-executive-team/2481428/EyeCheq, the developer of a fully autonomous eye screening platform using artificial intelligence (AI), announced that Jai G. Parekh, MD, FAAO, has been named Executive Vice-President and Chief Innovation Officer. Dr. Parekh, a dual-train
- EyePoint Pharmaceuticals Appoints Jay S. Duker, MD, as Chief Operating Officerhttps://modernod.com/news/eyepoint-pharmaceuticals-appoints-jay-s-duker-md-as-chief-operating-officer/2480387/EyePoint Pharmaceuticals announced the appointment of Jay S. Duker, MD, as Chief Operating Officer. Dr. Duker joined EyePoint as Chief Strategic Scientific Officer on a part-time basis in 2020, after having served as an independent member of EyePoint’s Board o
- Amring Pharmaceuticals Names Jai G. Parekh, MD, Chief Commercial Officer, Eye Care, UShttps://modernod.com/news/amring-pharmaceuticals-names-jai-g-parekh-md-chief-commercial-officer-eye-care-us/2482059/Amring Pharmaceuticals, a subsidiary of Nordic Group BV, has named Jai G. Parekh, MD, MBA, as Chief Commercial Officer, Eye Care, US. Nordic Pharma recently expanded its pharmaceutical presence in the US by acquiring Visant Medical, maker of the FDA-c
- EyePoint Pharmaceuticals Promotes Jay S. Duker, MD, to President and Chief Operating Officerhttps://modernod.com/news/eyepoint-pharmaceuticals-promotes-jay-s-duker-md-to-president-and-chief-operating-officer/2481320/EyePoint Pharmaceuticals announced that Jay S. Duker, MD, who has served as the company’s Chief Operating Officer (COO) since November 2021, has been promoted to the additional role of President. In addition to continuing to oversee his duties as COO, in his expanded role, Dr. Duker wi
- EyePoint Pharmaceuticals Names Jay S. Duker, MD, Chief Strategic Scientific Officerhttps://modernod.com/news/eyepoint-pharmaceuticals-names-jay-s-duker-md-chief-strategic-scientific-officer/2478005/EyePoint Pharmaceuticals announced the appointment of Jay S. Duker, MD, as Chief Strategic Scientific Officer. In this newly created role, Dr. Duker will lead the strategic advancement of our research and development efforts, beginning with our lead development candidate EYP-1901 for wet age-rela
